#1 Clinical Trials Search in Europe

Anhydrous Glucose Bp

This article discusses the use of Anhydrous Glucose BP in clinical trials, specifically focusing on a study investigating insulin resistance in kidney transplant recipients and patients with chronic kidney disease. The trial aims to assess the effects of Pravastatin on insulin sensitivity and related factors in these patient groups. Understanding the role of glucose in this context is crucial for evaluating the study’s methodology and potential outcomes.

Table of Contents

What is Anhydrous Glucose BP?

Anhydrous Glucose BP is a medical-grade form of glucose, which is a simple sugar that serves as a primary source of energy for your body. The “BP” in its name stands for “British Pharmacopoeia,” indicating that it meets specific quality standards. This substance is also known by its synonym, Glucose anhydrous BP.[1]

It’s important to note that in medical contexts, Anhydrous Glucose BP is often used interchangeably or in combination with Glucose Monohydrate Ph. Eur. (European Pharmacopoeia standard). Both forms are classified under the broader category of carbohydrates in medical terminology.[1]

Medical Uses

Anhydrous Glucose BP is primarily used in medical settings for various purposes:

  • Energy Source: It provides a quick source of energy for patients who cannot eat or drink normally.
  • Hydration: When mixed with water, it can help maintain proper hydration levels in the body.
  • Blood Sugar Regulation: In some cases, it may be used to treat low blood sugar (hypoglycemia).
  • Nutritional Support: It can be part of a broader nutritional therapy for patients who cannot receive nutrients orally.

While not directly related to Anhydrous Glucose BP, it’s worth noting that current research is exploring its potential role in studies related to insulin resistance, particularly in patients with kidney issues.[1]

How is it Administered?

Anhydrous Glucose BP is typically administered intravenously (IV), which means it’s given directly into a vein. This method allows for quick absorption and utilization by the body. The intravenous route is particularly useful in hospital settings or emergency situations where rapid delivery of glucose is necessary.[1]

Dosage Information

The dosage of Anhydrous Glucose BP can vary significantly depending on the patient’s specific needs and medical condition. However, based on the available information:

  • The maximum daily dose is typically up to 275 grams.
  • The maximum total dose over a treatment period can be up to 550 grams.
  • The maximum treatment period is usually around 2 days.[1]

It’s crucial to understand that these are maximum amounts, and actual doses are determined by healthcare professionals based on individual patient needs.

Current Research Focus

While the provided information doesn’t directly relate to new uses for Anhydrous Glucose BP, it does mention an ongoing study that might indirectly involve its use:

  • Insulin Resistance Study: Researchers are investigating the effects of a drug called Pravastatin on insulin sensitivity in kidney transplant recipients and patients with chronic kidney disease. While this study doesn’t directly use Anhydrous Glucose BP, it’s possible that glucose solutions might be used in the research process, particularly in procedures like the hyperinsulinemic euglycemic glucose clamp, which is mentioned as a primary endpoint.[1]

This research could potentially lead to new insights into how glucose is processed in patients with kidney issues, which might indirectly impact how Anhydrous Glucose BP is used in the future.

Important Considerations

When receiving Anhydrous Glucose BP or any glucose solution, it’s important to be aware of the following:

  • Medical Supervision: This product is administered under strict medical supervision, typically in a hospital or clinical setting.
  • Glucose Intolerance: Patients with hereditary glucose/galactose malabsorption should inform their healthcare providers, as this could affect how the body processes the glucose.[1]
  • Diabetes: If you have diabetes, your healthcare team will need to monitor your blood sugar levels closely when receiving glucose solutions.
  • Kidney Function: Patients with kidney issues may need special consideration when receiving glucose solutions, as the kidneys play a role in glucose regulation.

Always provide your full medical history to your healthcare team before receiving any treatment, including glucose solutions like Anhydrous Glucose BP.

Aspect Details
Trial Name Insulin Resistance and Statin Treatment in Renal Transplant Recipients and Patients with Chronic Kidney Disease
Main Objective To assess the effect of Pravastatin on insulin sensitivity compared to placebo
Primary Endpoint Insulin sensitivity assessed by hyperinsulinemic euglycemic glucose clamp
Study Population Kidney transplant recipients and patients with chronic kidney disease stage 3
Age Range 40-70 years
BMI Requirement 20-30 kg/m2
Key Exclusion Criteria Pre-existing diabetes, high blood pressure, active liver disease
Use of Anhydrous Glucose BP Part of the glucose clamp technique for measuring insulin sensitivity
Data Sharing Available to researchers with approved proposals for 5 years post-publication

FAQ

  • What is the main purpose of the clinical trial using Anhydrous Glucose BP? The main purpose is to assess the effect of Pravastatin on insulin sensitivity compared to placebo in kidney transplant recipients and patients with chronic kidney disease. Anhydrous Glucose BP is used in the hyperinsulinemic euglycemic glucose clamp technique to measure insulin sensitivity.
  • Who can participate in this clinical trial? The trial includes two studies. Study 1 is for kidney transplant recipients aged 40-70 years, with specific criteria such as BMI 20-30 kg/m2 and certain immunosuppressive treatments. Study 2 is for patients with chronic kidney disease stage 3, also aged 40-70 years and with similar BMI requirements.
  • Why is Anhydrous Glucose BP used in this trial? Anhydrous Glucose BP is used as part of the hyperinsulinemic euglycemic glucose clamp technique, which is the primary endpoint for measuring insulin sensitivity in the study participants.
  • What are some of the exclusion criteria for the trial? Some key exclusion criteria include pre-existing diabetes mellitus, high blood pressure (>160/100 mmHg), active liver disease, pregnancy or breastfeeding, and inability to provide informed consent. There are also specific exclusions related to medication use and previous reactions to statins.
  • How will the data from this trial be shared? The trial data will be shared with researchers who provide a methodologically sound proposal. Individual patient data will be shared after de-identification, along with study protocols and analytic code. Data may be requested for 5 years following article publication, subject to a data access agreement.

Ongoing Clinical Trials on Anhydrous Glucose Bp

  • Study on Pravastatin’s Effect on Insulin Resistance in Kidney Transplant and Chronic Kidney Disease Patients

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

Glossary

  • Anhydrous Glucose BP: A form of glucose (sugar) that does not contain water molecules. It is used in medical settings, including as part of glucose clamp techniques to measure insulin sensitivity.
  • Insulin Resistance: A condition where cells in the body don't respond well to insulin, making it harder to control blood sugar levels.
  • Chronic Kidney Disease (CKD): A condition characterized by gradual loss of kidney function over time.
  • eGFR: Estimated Glomerular Filtration Rate, a test used to check how well the kidneys are working.
  • Pravastatin: A medication belonging to the statin class, typically used to lower cholesterol levels.
  • Hyperinsulinemic Euglycemic Glucose Clamp: A technique used to measure insulin sensitivity by maintaining a constant blood glucose level while infusing insulin.
  • BMI: Body Mass Index, a measure that uses your height and weight to work out if your weight is healthy.
  • Immunosuppressive Treatment: Medications that lower the body's immune response, often used in transplant patients to prevent organ rejection.
  • Mycophenolate: An immunosuppressant drug used to prevent organ rejection in transplant patients.
  • Tacrolimus: Another immunosuppressant medication used to prevent organ rejection after transplantation.

References

  1. http://clinicaltrials.eu/trial/study-on-pravastatins-effect-on-insulin-resistance-in-kidney-transplant-and-chronic-kidney-disease-patients/